Oxandrolone in AIDS‐wasting myopathy

  title={Oxandrolone in AIDS‐wasting myopathy},
  author={Joseph R. Berger and Lorraine M. Pall and Colin D. Hall and David M. Simpson and Puja S. Berry and Robert E. Dudley},
Objective: To evaluate oxandrolone, an oral anabolic steroid with potent anabolic activity and minimal androgenic effects, for the treatment of AIDS‐associated myopathy and wasting. Methods: In a multicenter, double‐blind study, 63 HIV‐seropositive men with > 10% loss of body weight were randomized to receive either placebo, 5 mg/day oxandrolone, or 15 mg/day oxandrolone for 16 weeks. Body weight, neuromuscular evaluation, and measures of well‐being were repeatedly assessed. Results: Patients… 
Oxandrolone in ALS: Preliminary analysis
  • J. RosenfeldR. KingJ. Smith
  • Biology, Medicine
    Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases
  • 2000
Recent studies reveal that short-term administration of oxandrolone increases net protein synthesis in the muscle of healthy subjects, suggesting a possible mechanism for the enhanced protein synthesis.
The Anabolic Androgenic Steroid Oxandrolone in the Treatment of Wasting and Catabolic Disorders
Strong evidence of its clinical efficacy is provided and optimal risk: benefit ratios for oxandrolone and other agents in its class will need to be refined before widespread clinical acceptance of AASs as a therapeutic option in sarcopenia and other chronic wasting conditions.
Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar results in 2 months.
In conclusion, megestrol acetate therapy and oxandrolone therapy have similar effects on body weight and composition and are safe and well-tolerated during HAART.
Oxandrolone in the Treatment of HIV-Associated Weight Loss in Men: A Randomized, Double-Blind, Placebo-Controlled Study
Oxandrolone administration is effective in promoting dose-dependent gains in body weight and BCM in HIV-infected men with weight loss and was associated with significant suppression of sex hormone-binding globulin, luteinizing hormone, follicle-stimulating hormone, and total and free testosterone levels.
Anabolic Effects of Oxandrolone After Severe Burn
In burn victims, oxandrolone improves muscle protein metabolism through enhanced protein synthesis efficiency, suggesting the efficacy of ox androlone in impeding muscle protein catabolism in cachectic, critically injured children.
Thalidomide for the treatment of AIDS-associated wasting.
Thalidomide therapy was associated with mild to moderate rashes and fevers, but not peripheral neuropathy, and the anabolic benefits of high-dose thalidomides are limited by drug intolerance, 8 weeks of low- doses results in significant weight gain in patients with AIDS-associated wasting.
Metabolic and Hormonal Changes of Severely Burned Children Receiving Long-Term Oxandrolone Treatment
Oxandrolone improved body composition and strength in severely burned children during the 12 months of treatment and its effect on height and weight continued after treatment was discontinued.
Low dihydrotestosterone and weight loss in the AIDS wasting syndrome.
A syndrome of low DHT withnormal testosterone was associated with significantly greater weight loss than in patients with normal testosterone and DHT, and whether androgen therapy in the form of DHT could reverse some of the metabolic changes associated with AIDS wasting.
Oxandrolone, an anabolic steroid, significantly increases the rate of weight gain in the recovery phase after major burns.
It is concluded that an anabolic steroid combined with increased protein intake can significantly increase the rate of restoration of weight gain postburn.